NewsTarget RWE Strengthens Leadership Team with Appointments Across Delivery, Finance and CommercialRead more →Read more →
Target RWE Strengthens Leadership Team with Appointments Across Delivery, Finance and CommercialRead more →
How does causalStudio™ address the key regulatory requirements for data integrity, traceability, and analysis?Read more →
An Overview of MASH: Advancements in Diagnosis, Treatment, and the Role of Real-World DataRead more →
Addressing the Burden of Hidradenitis Suppurativa: The Often-Hidden Impact on Quality of LifeRead more →
AASLD Opens Call for Applications for Sites to Participate in TARGET-LD and the Cirrhosis Quality Collaborative (CQC Data Registry)Read more →
Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology StudiesRead more →
New Patient-Reported Outcome Insights from Target RWE: NASH-CHECK Reveals Stability Over Time and Worse Scores Among Those with Decompensated Cirrhosis of Patients with MASLDRead more →
Target RWE Highlights GLP-1 Receptor Agonists in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease at The Liver Meeting 2024Read more →
ACG 2024: Target RWE Presents Key MASH and EGIDs Data from Leading Liver Disease & Gastroenterology Real-World RegistriesRead more →
Target RWE Unveils Latest Developments in TARGET-Liver Disease and Cirrhosis Quality Collaborative Partnership with the American Association for the Study of Liver DiseasesRead more →
Transforming Healthcare Through Data: Ewa J. Kleczyk on Precision Medicine, Diversity, and AI ChallengesRead more →
Target RWE Announces the Launch of engage™ - An Innovative, Digital Patient-Centric Engagement PlatformRead more →
Real World TARGET-NASH Analysis Shows High Concordance Between New MASLD Definitions and Prior TARGET-NASH Pragmatic DefinitionsRead more →
GLP-1 Use and NASH-CHECK Patient-Reported Outcomes Studies from Target RWE Presented at EASL 2024Read more →
World's Largest Liver Disease-Focused Registry Surpasses 400,000 Patient Enrollment MilestoneRead more →
Real-World Evidence Leader in Inflammatory Bowel Disease, Target RWE, Announces Expanded Footprint with TARGET-GASTRO Registry of 30,000+ Patients At Digestive Disease WeekRead more →
AGA Announces New Partnership with Target RWE to Gather Real World Data on Eosinophilic Esophagitis (EoE)Read more →
Patient-Reported Outcomes Data from Longest Running Dermatology Study: TARGET-DERM AA Poster Presented at American Academy of Dermatology (AAD) 2024Read more →
Target RWE Launches Novel Precision Medicine Platform to Undertake Growing Unmet Medical Needs in Liver Disease, Gastroenterology, and Immune-mediated Inflammatory ConditionsRead more →
Overcoming Scalability Challenges in Real-World Data Processing for Transformative Patient CareRead more →
TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment OptionsRead more →
Target RWE Releases Important Updates on the Cirrhosis Quality Collaborative/TARGET-Liver Disease Partnership with the American Association for the Study of Liver DiseasesRead more →
Leveraging Real-World Evidence with Analytics: 3 Essential Components to Capture a 360-Degree View of Your Patient PopulationRead more →
New Eosinophilic Gastrointestinal Disorders (EGIDs) Real World Registry Surpasses 1,000 Patient MilestoneRead more →
World-Leading Real World Data Registry, TARGET-NASH, Surpasses 7,000+ Enrolled Patients and 500,000+ Months of Patient Follow-UpRead more →
Event Recap Blog: TARGET-NASH Analysis Presented at ISPOR 2023 and Target RWE Leaders Present at PMSA 2023Read more →
Real World Evidence Leader Target RWE Shares Expansion and Update on TARGET-GASTRO Longitudinal Study During Digestive Disease Week 2023Read more →
Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASHRead more →
Ewa Kleczyk, PhD Featured on CIO Views Cover for March – A Memento to Women's History Month & International Women's DayRead more →
Longest Running Real World Dermatology Registry, TARGET-DERM, Offers Deep Insight into Complex DiseasesRead more →
Target RWE and the American Association for the Study of Liver Diseases Announce Research Agreement for Cirrhosis Quality CollaborativeRead more →
New Approaches for Developing Real-World Evidence Presented by Target RWE at the 2022 International Conference on Pharmacoepidemiology (ICPE)Read more →
Durham-Based Target RWE Grows Data Abstraction, Curation Capabilities with Latest AcquisitionRead more →
Target RWE New Brand, Research, and Advanced Real World Evidence Analytics Showcased at International Conference on Pharmacoepidemiology (ICPE) 2022Read more →
Real-World Data Finds High Prevalence of Pruritus (Itching) and Fatigue, Low Levels of Treatment in Primary Biliary Cholangitis PopulationRead more →
Nonalcoholic Fatty Liver Disease (NAFLD) Research from Target RWE's Real-World Study Presented at International Liver Congress 2022Read more →
New Data Presented at DDW 2022 Shows Nearly Two-Fold Risk of Loss of Remission in Ulcerative Colitis Patients Who Had Histologic Inflammation on Baseline BiopsyRead more →
Large Real-World Study Uncovers Higher Prevalence of Non-Alcoholic Fatty Liver Disease Markers, Liver Biopsy, and Cirrhosis in ChildrenRead more →
TARGET-IBD Study Reveals Nearly a Third of Patients with Inflammatory Bowel Disease Did Not Undergo Objective Assessment Prior to Biologic Dose Change, DiscontinuationRead more →
Peer-Reviewed Target RWE Study Finds Wide Variance in Nonalcoholic Steatohepatitis (NASH) Pathology ReportingRead more →
Update from Paris NASH 2021: New Target RWE Nonalcoholic Steatohepatitis (NASH) Data Presented at This Year's MeetingRead more →
Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and SciencesRead more →
Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger PatientsRead more →
TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart DiseaseRead more →
Target RWE COVID-19 Data: Real-World Evidence Analysis Shows 3.6% of COVID-19 Hospitalized Patients Discharged Alive Required ReadmissionRead more →
Target RWE Research Presented at DDW 2021 Shows High Rates of Biologic Combination Therapy and Previous Biologic Exposure in IBD PopulationRead more →
TARGET-NASH Real-World Study Reveals Two Thirds Of Patients With NAFLD Had No Record Of Liver BiopsyRead more →
Target RWE Acquires NoviSci Inc., Adding Significant Analytical Capabilities to Leading Real-World Evidence PlatformRead more →
Target RWE Data Presented at AASLD Virtual Meeting Provides Important Updates for NASH and PBC CommunitiesRead more →
TARGET-DERM Real-World Study Success Leads To Global Site Expansion And New Dermatologic ConditionsRead more →
TARGET-NASH Data Publication Finds Nearly One In Five Patients With NAFLD Have Prior Prescription Opioid UseRead more →
Asian Lean Patients With NAFLD Are 53% Less Likely To Have Cirrhosis, Cardiovascular, And Metabolic Diseases - Latest Data Findings Released From TARGET-NASH StudyRead more →
Target RWE Builds Growing COVID-19 Data Set of 70,000+ Patients, Announces Published Data FindingsRead more →
TARGET PharmaSolutions Expands TARGET-DERM Research Community with Two New Industry PartnershipsRead more →
TARGET-IBD Research Receives Presidential Poster Award And Outstanding Presenter Award At 2019 American College Of Gastroenterology Annual Scientific MeetingRead more →
TARGET PharmaSolutions to Advance Dermatology Research, including Atopic Dermatitis, through New CollaborationRead more →
TARGET PharmaSolutions Launches TARGET-DERM Real-World Observational Study to Advance the Understanding of Atopic Dermatitis (Eczema) and Other Immune-Mediated Inflammatory Skin ConditionsRead more →
TARGET PharmaSolutions Announces Partnership with Bristol Myers Squibb to Advance Inflammatory Bowel Disease (IBD) ResearchRead more →
TARGET PharmaSolutions to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead SciencesRead more →
TARGET PharmaSolutions Initiates a New Community, TARGET-HBV, to Advance the Understanding of Hepatitis BRead more →
Why big pharma is partnering with this Chapel Hill data company - Triangle Business JournalRead more →
Intercept (ICPT) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASHRead more →
Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASHRead more →
TARGET PharmaSolutions Enrolls First Participant in its Inflammatory Bowel Disease (IBD) CommunityRead more →
TARGET PharmaSolutions Partners with Bristol-Myers Squibb, Offering a New Platform to Collect Real World DataRead more →
Intercept Announces OCALIVA (OBETICHOLIC ACID) Data in PBC to be Presented at the 2016 AASLD Annual MeetingRead more →
